Neuropathy Action Foundation Advocates for Enhanced Access to Lifesaving Plasma-Derived Medicines

Neuropathy Action Foundation Advocates for Enhanced Access to Lifesaving Plasma-Derived Medicines



On November 17, 2026, the Neuropathy Action Foundation (NAF) released an important white paper titled "Improving Access to Plasma-Derived Therapies for Neuropathy." This document highlights significant obstacles that patients with neuropathic conditions face in accessing essential plasma-derived medications. Key issues identified include outdated state regulations, challenges in plasma supply, and restrictive insurance policies. The NAF has collaborated with M2 Health Care Consulting to produce this critical assessment.

The paper draws attention to the fact that over 20 million Americans suffer from neuropathy in various forms. For individuals dealing with immune-mediated neuropathies such as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Guillain-Barré Syndrome (GBS), and Multifocal Motor Neuropathy (MMN), plasma-derived therapies are often the first line of defense. According to Brenda Gleason, President of M2 Health Care Consulting, "The United States is responsible for more than 70% of the world's plasma supply, yet vulnerabilities across the supply chain complicate its availability." Gleason stresses the necessity for comprehensive policies that can foster a safe plasma supply and enhance patient access to the medications they require.

The white paper elaborates on the intricate nature of the plasma supply chain, which starts with human donors and concludes with the manufacturing of the finished medicines, a process that can last up to a year. It also notes several recent successes in legislation, including California's Assembly Bill 2009 and Connecticut's Senate Bill 368, which aim to modernize regulations regarding source-plasma collection while safeguarding donor safety and ensuring product quality.

However, a stable plasma ecosystem alone does not resolve the challenges faced by patients. Many individuals grapple with issues such as insurance denials, daunting criteria for medical necessity, and suffocating prior authorization requirements that force them to trial other treatments before being approved for their prescribed therapies. Dominick Spatafora, Founder and President of the Neuropathy Action Foundation, who personally experiences Multifocal Motor Neuropathy, shared his own struggles with access to intravenous immunoglobulin (IVIg) treatments. He expressed that the denial he faced created feelings of fear, frustration, and uncertainty—emotions many patients experience when their necessary treatments are suddenly inaccessible.

Spatafora insists that improving access involves addressing the entire system governing plasma supply, donor contributions, and insurance policies affecting treatment availability. He emphasizes that only by aligning all facets of this ecosystem can patients gain unimpeded access to their individualized treatments, allowing them to live fulfilling and independent lives.

To read the full white paper, visit the Neuropathy Action Foundation’s website

About Neuropathy Action Foundation


The Neuropathy Action Foundation is a 501(c)(3) nonprofit organization dedicated to ensuring that neuropathy patients have the resources and information they need to access individualized treatment that improves their quality of life. The foundation aims to raise awareness among healthcare providers, the general public, and policymakers about the seriousness of neuropathy and its treatability through appropriate care. For further information, please visit www.neuropathyaction.org.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.